Moon Surgical has announced that its Maestro™ System has received FDA clearance for commercial use. This milestone marks a significant leap forward in Moon’s ascent in robot-assisted laparoscopic surgery, promising to enhance the precision and efficiency of various surgical procedures.

The Maestro™ system is designed to assist surgeons in performing minimally invasive procedures with greater accuracy and control. Moon’s innovative technology aims to reduce the physical strain on surgeons, minimize patient recovery time, and improve overall surgical outcomes.

The Maestro™ system has already shown promising results in Europe, where it is currently being used for general, bariatric, and OB/GYN procedures. This versatility underscores the Maestro System's potential to become a staple in operating rooms worldwide, catering to a diverse range of surgical needs. With the FDA's nod, the company is poised to commercialize the platform in the United States and attempt to revolutionize the way laparoscopic surgeries are conducted worldwide.

Analyst Insights: Moon’s Unique Approach to Revolutionizing Laparoscopic Surgery

In a competitive commercial marketplace, what may set the Maestro™ system apart is its surgeon-centric design. Moon Surgical has crafted a system that is designed to complement the surgeon's laparoscopic expertise, rather than replace it. The novel interface and ergonomic design allow for seamless integration into existing surgical workflows. Surgeons may also be able perform complex procedures with enhanced precision, thanks to the system's advanced robotic assistance.

According to LSI's Global Market Analysis and Projections (MAP), the laparoscopic robotics market is valued at approximately $7 billion and is forecasted to grow at a robust rate of 17.3% from 2023 to 2028. This strong growth trajectory highlights the opportunity and increasing demand for advanced surgical solutions like the Maestro™ System, the growing number of medical device companies building in the space, and the medical device investors financing these solutions.

Focusing on soft tissue procedures is a prudent strategy. The system's current use in Europe for general, bariatric, and OB/GYN procedures positions it well to capitalize on these expanding market segments. Notably, bariatric surgeries are one of the fastest-growing markets, with a worldwide compound annual growth rate (CAGR) of 9.0%. This market is rapidly approaching over 1 million procedures worldwide, according to LSI’s Global Procedure Volumes Database. The United States is the largest market by volume, followed by India, France, and Germany.

More on Moon Surgical

Moon Surgical has been one of the emerging medical device companies selected to present at previous LSI events, including LSI Europe ‘23 and LSI Europe ‘22. This September, the European edition of LSI’s premier medtech conference will be held in Sintra, Portugal. The event will convene hundreds of medtech companies like Moon Surgical alongside top medical device venture capital firms and private equity investors, global strategics, and more. 

Content from Moon Surgical’s presentations, studio interviews and panels is available from LSI’s  medtech market research team on our website:

• Jeffery Alvarez, Moon Surgical - Spotlight Interview | LSI Europe ‘23

• The New Standard of Care: What Market Opportunities Are Ripe for the Next Generation of Digital Surgery? | LSI Europe '23

• Anne Osdoit, Moon Surgical - Laparoscopic Surgical Robot | LSI Europe '22

• Robotics Innovation & Investment Trends | LSI Europe '22

A proprietary profile on Moon Surgical is also available in LSI’s Companies & Deals database, providing coverage of over 6,000 medical device companies. Coverage includes full company profiles, associated deals, executive summaries, and more proprietary content from LSI events. Visit our website to learn more about our Companies & Deals database and full suite of medtech market research solutions.